Provided by Tiger Fintech (Singapore) Pte. Ltd.

Stoke Therapeutics, Inc.

8.61
+0.920011.96%
Volume:1.73M
Turnover:14.68M
Market Cap:465.61M
PE:-5.23
High:8.91
Open:7.57
Low:7.48
Close:7.69
Loading ...

Stoke Therapeutics remains significantly undervalued, says Canaccord

TIPRANKS
·
31 Mar

Earnings Beat: Stoke Therapeutics, Inc. (NASDAQ:STOK) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

Simply Wall St.
·
22 Mar

Stoke Therapeutics Price Target Maintained With a $22.00/Share by Needham

Dow Jones
·
19 Mar

Stoke Therapeutics CEO Edward Kaye Steps Down; Interim CEO Named

MT Newswires Live
·
18 Mar

Stoke Therapeutics Chief Executive Edward Kaye Stepping Down

Dow Jones
·
18 Mar

Stoke Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

Business Wire
·
18 Mar

BRIEF-Stoke Therapeutics Appoints Director Ian F. Smith Interim Chief Executive Officer

Reuters
·
18 Mar

Stoke Therapeutics Inc: Arthur Tzianabos Appointed Interim Executive Chairman of Board

THOMSON REUTERS
·
18 Mar

Stoke Therapeutics Announces CEO Transition

Business Wire
·
18 Mar

Top Premarket Decliners

MT Newswires Live
·
11 Mar

Stoke Therapeutics to Present at Upcoming Investor Conferences in March

Business Wire
·
27 Feb

We're Hopeful That Stoke Therapeutics (NASDAQ:STOK) Will Use Its Cash Wisely

Simply Wall St.
·
26 Feb

Analysts Conflicted on These Healthcare Names: Halozyme (HALO), Stoke Therapeutics (STOK) and Lantheus (LNTH)

TIPRANKS
·
23 Feb

Chardan Capital Sticks to Their Buy Rating for Stoke Therapeutics (STOK)

TIPRANKS
·
19 Feb

Biogen Strengthens Pipeline With Stoke Therapeutic's Dravet Syndrome Candidate Via Multi-Million Dollar Deal

Benzinga
·
19 Feb

Stoke Therapeutics Price Target Maintained With a $22.00/Share by Needham

Dow Jones
·
19 Feb

HC Wainwright Adjusts Price Target on Stoke Therapeutics to $47 From $35, Maintains Buy Rating

MT Newswires Live
·
18 Feb

BRIEF-Biogen And Stoke Therapeutics Enter Into Collaboration

Reuters
·
18 Feb

Stoke Therapeutics Shares up 3.5% After Co Enters Partnership With Biogen to Develop, Sell Epilepsy Drug

THOMSON REUTERS
·
18 Feb

Biogen Shares up About 1%

THOMSON REUTERS
·
18 Feb